- Published at
- by manilatimes.net
negative
negative
News for Can-Fite BioPharma Ltd. (CANF.TA)
- Published at
- by gurufocus.com
neutralneutralFollowing FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients | CANF Stock News
FDA grants compassionate use approval for Namodenoson in pancreatic carcinoma. Increased interest from leading U.S. medical centers pursuing sim- Published at
- by manilatimes.net
negativenegative- Published at
- by gurufocus.com
positivepositiveCan-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares | CANF Stock News
Can-Fite BioPharma Ltd. announces a $3.0 million registered direct offering of American Depositary Shares (ADSs). The company will issue 2,500,000 ADSs- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveCan-Fite to Generate $685M in Projected Future Revenues from its Partnerships | CANF Stock News
Can-Fite BioPharma (CANF) projects $685 million in revenue from partnerships over the next decade. The forecast covers key drug candidates targeting pso- Published at
- by gurufocus.com
positivepositiveCan-Fite Reports 2024 Financial Results and Clinical Update | CANF Stock News
Can-Fite BioPharma (CANF) reports a notable complete cancer remission in a liver cancer patient treated with Namodenoson. Namodenoson receives FDA Orpha- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
negativenegative- Published at
- by manilatimes.net
negativenegative- Published at
- by manilatimes.net
negativenegative- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
neutralneutralCan Fite Biopharma stock hits 52-week low at $1.86 By Investing.com
Can Fite Biopharma stock hits 52-week low at $1.86- Published at
- by manilatimes.net
negativenegative- Published at
- by gurufocus.com
mixedmixed60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma- Published at
- by investing.com
neutralneutralCan-Fite secures Australian patent for obesity treatment By Investing.com
Can-Fite secures Australian patent for obesity treatment- Published at
- by globenewswire.com
neutralneutralCan-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd....- Published at
- by manilatimes.net
negativenegative- Published at
- by globenewswire.com
negativenegativeSignificant Positive Results from Osteoarthritis Clinical
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan,...